R&D channel feed

Ra­dius fal­ters af­ter a PhI­II os­teo­poro­sis fail and a breast can­cer dis­ap­point­ment, send­ing shares plum­met­ing

4 years ago

Strug­gling Aprea wins a re­prieve as FDA lifts one of the holds on their on­ly drug

4 years ago

House al­most unan­i­mous­ly pass­es bi­par­ti­san bill to pump $500M in­to ALS drug R&D

4 years ago

FDA ad­comm votes unan­i­mous­ly against Reata's po­ten­tial Al­port syn­drome treat­ment

4 years ago
FDA+

New stud­ies in­di­cate mR­NA vac­cines pro­vide lim­it­ed pro­tec­tion against Omi­cron, but boost­ers and new shots may be cru­cial

4 years ago
Coronavirus

Mer­ck pumps the brakes on two more PhI­II tri­als for its lead an­ti-HIV drug

4 years ago

Aca­dia touts late-stage win for its Rett syn­drome drug, edg­ing out a lead against its com­peti­tors

4 years ago

Bolt Bio goes bust as in­vestors boo sin­gle re­sponse in ear­ly test against HER2-ex­press­ing tu­mors

4 years ago

Adicet un­veils ear­ly re­spons­es for off-the-shelf drug lever­ag­ing rare T cells. Will dura­bil­i­ty hold up?

4 years ago
Cell/Gene Tx

Ae­glea's en­gi­neered en­zyme flops out­comes test in rare meta­bol­ic dis­ease. Is re­duc­ing a key bio­mark­er enough for an ap­proval?

4 years ago

Pfiz­er, Am­gen and Janssen seek fur­ther clar­i­ty on FDA's new ben­e­fit-risk guid­ance

4 years ago
FDA+

Stoke touts ear­ly signs of ef­fi­ca­cy for Dravet syn­drome drug

4 years ago

With gener­ic com­pe­ti­tion heat­ing up, Vas Narasimhan out­lines No­var­tis' growth plans at R&D day

4 years ago

VBI Vac­cines ex­ecs tout ap­proval of new triple-anti­gen he­pati­tis B shot. Can they sell it?

4 years ago
FDA+

Bat­tling a line­up of skep­tics, Ver­tex claims an­oth­er ear­ly clin­i­cal win — this time in kid­ney dis­ease

4 years ago

As lead drug runs in­to a wall, De­ci­phera slims down its pipeline, puts 140 jobs on the chop­ping block

4 years ago
People

Im­muno­Gen touts a PhI­II come­back in ovar­i­an can­cer, eye­ing a 2022 ac­cel­er­at­ed ap­proval

4 years ago
FDA+

How to use reg­istry da­ta to sup­port FDA de­ci­sion mak­ing: Agency ex­plains in new guid­ance

4 years ago
FDA+

Af­ter re­fut­ing a sup­posed da­ta leak as 'fal­si­fied', Ole­ma re­veals first clin­i­cal da­ta for lead pro­gram — shares crash

4 years ago

'This is not go­ing to be good': Mod­er­na CEO Ban­cel warns of a 'ma­te­r­i­al drop' in vac­cine ef­fi­ca­cy as Omi­cron spreads

4 years ago

BD an­nounces an­oth­er ex­pan­sion, this time in San Diego

4 years ago

FDA hits the red light on an ear­ly-stage AML study af­ter a pa­tient dies

4 years ago
FDA+

Mer­ck­'s pause on an HIV pro­gram snow­balls as a Gilead-part­nered tri­al is shoved in­to lim­bo

4 years ago
Deals

J&J’s neu­ro­science re­nais­sance? Janssen R&D chief ready­ing for 'gold­en age'

4 years ago
Pharma
Marketing
First page Previous page 152153154155156157158 Next page Last page
A service from the Financial Times